ION Exchange Q2 FY27: Net Loss Widens to ₹828 Million Amidst Legacy Project Impact
ION Exchange reported Q2 FY27 net loss of ₹828 million, impacted by legacy project costs. Operating income declined 8% to ₹6,747 million. H1 FY27 net loss was ₹797 million. Order book stands at ₹29,690 million. Treatment Solutions revenue fell due to project cost overruns.
The substantial net loss and the impact of legacy project cost overruns on a key segment are material events that will likely affect investor sentiment and the company's financial outlook.
The company reported a significant net loss for the quarter and half-year, primarily due to cost overruns in legacy projects. While some segments showed growth, the overall financial performance was negative.
ION Exchange (India) Limited announced its financial results for the second quarter and the first half ended September 30, 2026. The company reported an operating income of ₹6,747 million for Q2 FY27, a decline of approximately 8% year-on-year. The EBITDA for the quarter was a loss of ₹848 million, and the net loss after tax stood at ₹828 million. This performance was significantly impacted by changes in the estimated cost to complete for certain legacy projects within the Treatment Solutions segment.
For the first half of FY27, operating income was ₹13,752 million, a growth of just under 4% year-on-year. The EBITDA for H1 FY27 was a loss of ₹530 million, with a net loss after tax of ₹797 million.
The company's order book as of September 30, 2026, stood at approximately ₹29,690 million, including an international contract from Hyundai Engineering and Construction Company Limited valued at USD 52.83 million for filtration units. The bid pipeline was ₹93,700 million.
Segment-wise, Treatment Solutions reported revenue of ₹1,498 million in Q2 FY27, down from ₹2,958 million in the corresponding quarter last year, with EBIT at a loss of ₹1,215 million. This was attributed to cost overruns on legacy projects and deferred dispatches due to the Middle East crisis. The Industrial Products segment showed strong growth with revenue up 35% year-on-year to ₹1,360 million. Specialty Chemicals revenue grew by approximately 17% to ₹2,546 million, though margins were under pressure due to input cost inflation. The Consumer Product segment saw revenue increase by approximately 30% to ₹1,005 million.
Management indicated that the Treatment Solutions segment's performance was significantly impacted by legacy contracts, with a substantial portion of the quarter's negative PBT attributed to this. They expect an improvement in turnover and margins in the second half of the year for this segment. The Roha plant in the Specialty Chemicals segment is facing headwinds from input cost inflation due to the West Asia crisis, but steps are being taken to pass on costs. The Consumer Product division is projected to reach break-even during the current financial year.
What to do with a filing like this
ION Exchange (India) Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by ION Exchange (India) Limited. Read the original for the full detail.